Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


PacBio's New HiFiViral Surveillance Kit Performance Is Not Impacted By Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes For All Circulating Variants


Benzinga | Dec 28, 2021 09:10AM EST

PacBio's New HiFiViral Surveillance Kit Performance Is Not Impacted By Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes For All Circulating Variants

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate, long-read sequencing technology, today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced and captured the entire genome of the SARS-CoV-2 Omicron variant lineage. The solution gives researchers around the globe a powerful tool to access complete genomic information on Omicron, without gaps in sequencing information that can result from mutations that occur along the SARS-CoV-2 virus genome.



"Detecting the Omicron lineage is simply not enough to understand the full impact of this variant on public health," said Christian Henry, Chief Executive Officer and President of PacBio. "Having a complete picture of the Omicron mutations will help public health entities better answer critical questions about how similar Omicron is to other variants, its transmissibility, spread, implications for vaccine breakthrough, and potential occurrences of additional genome changes."

HiFiViral uses molecular inversion probes, a differentiated viral enrichment approach that provides deep, redundant coverage across the entire SARS-CoV-2 genome for robust detection of all existing variants, and of new variants as they emerge. By contrast, current PCR amplicon-based methods, whether used by short-read or other long-read technologies, can be affected by new variants that result in gaps in the genome sequence, requiring periodic updates and revalidation to keep pace with the evolving virus.

Several customers have validated the HiFiViral SARS-CoV-2 kit and have confirmed it performs well on Omicron variants. This week, scientists at Inqaba Biotec in South Africa successfully sequenced 35 Omicron samples and obtained >95% coverage for 29 samples. These results were consistent with the performance of the HiFiViral SARS-CoV-2 kit on Delta and other variants. Most notably, there were no systematic gaps in the mutation-rich spike region, confirming in silico predictions that the unique, densely tiled probe design of the HiFiViral SARS-CoV-2 kit is robust to highly divergent variant lineages.

"We were able to successfully sequence Omicron in our lab and reliably get complete coverage of the entire genome, including the highly mutated gene responsible for the Spike protein. It's important to have this level of resolution to understand the full impact of this variant. The workflow was also very simple which allowed us to process, analyze, and turn around results in a rapid and efficient way that we couldn't get from PCR-amplicon based methods," said Dr. Hamilton Ganesan, Bioinformatics Manager at Inqaba Biotec.

The HiFiViral kit provides a powerful tool to scientists around the world who are racing to understand the impact of new variants. In addition to providing better data to researchers, the kit's workflow requires less time and labor, and substantially fewer plastics and other consumables than other technologies - reducing potential supply chain bottlenecks that have challenged surveillance laboratories.

"The HiFiViral kit is available worldwide and represents a major step forward in helping labs fight the COVID-19 pandemic," Henry said. "We believe it will be essential in future-proofing labs against new variants."






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC